教員情報 - 木川　雄一郎

（最終更新日：2024-04-24 11:57:18）

  キカワ　ユウイチロウ   KIKAWA YUUICHIRO
  木川　雄一郎
   所属   関西医科大学乳腺外科学講座

職種診療講師

■ 学術雑誌掲載論文

1.	原著(症例報告除く)	Pilot trial of an electronic patient-reported outcome monitoring system in patients with metastatic breast cancer undergoing chemotherapy 2024/03
2.	原著(症例報告除く)	Reliability and validity of the Japanese version of the Chemotherapy-induced Alopecia Distress Scale 2024/03
3.	原著(症例報告除く)	Identifying prognostic biomarkers for palbociclib add-on therapy in fulvestrant-resistant breast cancer using cell-free DNA sequencing 2024/02
4.	原著(症例報告除く)	Changes in cell-free DNA after short-term palbociclib and fulvestrant treatment for advanced or metastatic hormone receptor-positive and human epidermal growth factor 2-negative breast cancer 2024/01
5.	原著(症例報告除く)	De-differentiation in cultures of organoids from luminal-type breast cancer is restored by inhibition of NOTCH signaling 2023/11
6.	原著(症例報告除く)	The Japanese Breast Cancer Society Clinical Practice Guidelines for systemic treatment of breast cancer, 2022 edition 2023/11
7.	原著(症例報告除く)	Development and validation of a symptom illustration scale from the patient-reported outcome common terminology criteria for adverse events for patients with breast cancer 2023/09
8.	症例報告	Dramatic Recovery of Vision after Trastuzumab Deruxtecan Treatment of HER2-Positive Breast Cancer with Pituitary Metastasis 2023/07
9.	原著(症例報告除く)	Patient-reported outcome and quality of life research policy: Japan Clinical Oncology Group (JCOG) policy 2023/03
10.	原著(症例報告除く)	Association of change in health-related quality of life and treatment discontinuation in metastatic breast cancer: a post hoc, exploratory analysis of two randomized clinical trials 2022/10
11.	原著(症例報告除く)	Effectiveness of eribulin as first-line or second-line chemotherapy for HER2-negative hormone-resistant advanced or metastatic breast cancer: findings from the multi-institutional, prospective, observational KBCRN A001: E-SPEC study 2022/09
12.	原著(症例報告除く)	Switch maintenance endocrine therapy plus bevacizumab after bevacizumab plus paclitaxel in advanced or metastatic oestrogen receptor-positive, HER2-negative breast cancer (BOOSTER): a randomised, open-label, phase 2 trial. 2022/04
13.	原著(症例報告除く)	Cancer patient satisfaction with health care professional communication. An international EORTC study 2021/09
14.	原著(症例報告除く)	Quality of life in a randomized phase II study to determine the optimal dose of 3-week cycle nab-paclitaxel in patients with metastatic breast cancer 2021/09
15.	その他	【10年後の乳がん診療】乳がん薬物療法におけるQOL評価 2021/09
16.	原著(症例報告除く)	Eribulin-based neoadjuvant chemotherapy for triple-negative breast cancer patients stratified by homologous recombination deficiency status: a multicenter randomized phase II clinical trial. 2021/05
17.	症例報告	IgG4関連疾患疑診群の1例 2021/03
18.	原著(症例報告除く)	Secondary endpoints analysis in patients with estrogen receptor-positive metastatic breast cancer treated with everolimus and exemestane enrolled in Oral Care-BC 2021/01
19.	原著(症例報告除く)	Randomized phase II study to determine the optimal dose of 3-week cycle nab-paclitaxel in patients with metastatic breast cancer. 2021
20.	原著(症例報告除く)	Real-World Outcomes of Treating Advanced Breast Cancer Patients With Palbociclib: A Multicenter Retrospective Cohort Study in Japan-The KBCOG-14 Study 2020/12
21.	その他	【性ホルモンと産生・依存性腫瘍の基礎と臨床】性ホルモン依存性悪性腫瘍　エストロゲンと乳癌　乳癌の発生から最新分子標的治療まで 2020/06
22.	原著(症例報告除く)	The efficacy of sequential second‑line endocrine therapies (ETs) in postmenopausal estrogen receptor‑positive and HER2‑negative metastatic breast cancer patients with lower sensitivity to initial ETs 2020/05
23.	原著(症例報告除く)	Oral Care Evaluation to Prevent Oral Mucositis in Estrogen Receptor-Positive Metastatic Breast Cancer Patients Treated with Everolimus (Oral Care-BC): A Randomized Controlled Phase III Trial 2020/02
24.	原著(症例報告除く)	Baseline neutrophil-to-lymphocyte ratio and c-reactive protein predict efficacy of treatment with bevacizumab plus paclitaxel for locally advanced or metastatic breast cancer 2020
25.	原著(症例報告除く)	Effectiveness and safety of surgical glove compression therapy as a prophylactic method against nanoparticle albumin-bound-paclitaxel-induced peripheral neuropathy. 2019/07
26.	原著(症例報告除く)	Evaluation of health-related quality of life via the Computer-Based Health Evaluation System (CHES) for Japanese metastatic breast cancer patients: a single-center pilot study. 2019/03
27.	原著(症例報告除く)	Clinical Predictive Factors for the Efficacy of Everolimus in Patients With Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer: A Multicenter Retrospective Cohort Study in Japan 2019/01
28.	原著(症例報告除く)	Acute Liver Failure with Diffuse Liver Metastasis from Breast Cancer, Not Detected by Computed Tomography: 2 Case Reports. 2018/10
29.	原著(症例報告除く)	Hormonal Therapy Resistant Estrogen-receptor Positive Metastatic Breast Cancer Cohort (HORSE-BC) Study : Current Status of Treatment Selection in Japan. 2018/08
30.	原著(症例報告除く)	Body mass index and menopausal disorders during menopause affect vasomotor symptoms of postmenopausal Japanese breast cancer patients treated with anastrozole: a prospective multicenter cohort study of patient-reported outcomes. 2017/07
31.	原著(症例報告除く)	Prevalence of hypothyroidism among patients with breast cancer treated with radiation to the supraclavicular field: a single-centre survey. 2017/04
32.	原著(症例報告除く)	Evaluation of the effect of compression therapy using surgical gloves on nanoparticle albumin-bound paclitaxel-induced peripheral neuropathy: a phase II multicenter study by the Kamigata Breast Cancer Study Group. 2016/11
33.	原著(症例報告除く)	Risk factors for joint symptoms in postmenopausal Japanese breast cancer patients treated with anastrozole: a prospective multicenter cohort study of patient-reported outcomes. 2015/09
34.	症例報告	Angiosarcoma of the Breast – specific findings of MRI 2006
5件表示
全件表示(34件)

■ 学会発表

1.	ホルモン受容体陽性HER2陰性乳癌における術後S-1の位置づけ（口頭，特別講演・招待講演など） 2023/06
2.	HR陽性HER２陰性乳癌における術後薬物治療の位置づけ（口頭，特別講演・招待講演など） 2023/04
3.	患者の声を現場に還元するー質的研究の課題と今後ー（口頭，シンポジウム・ワークショップパネル（その他）） 2023/03
4.	Quality of life in MBC patients treated with Eribulin （口頭，特別講演・招待講演など） 2023/02
5.	遺伝学的検査結果の解釈に難渋したBRCA2病的バリアントの1例（ポスター掲示，一般） 2022/12
6.	原発乳癌リンパ節転移陽性患者における術前化学療法後腋窩郭清省略の多施設共同研究-LEISTER ｓtudy- （口頭，シンポジウム・ワークショップパネル（その他）） 2022/11
7.	当院における乳癌遺伝子診療の現状と今後の展望（ポスター掲示） 2022/07
8.	Luminal typeにおける早期ラインとしてのエブリンの可能性（口頭，特別講演・招待講演など） 2022/03
9.	転移性乳癌の薬物療法におけるShared Decision　Makinngの実践」（口頭，一般） 2022/03
10.	乳がん症例における治療マネジメントの検討（口頭） 2021/03
11.	保険診療における BRCA1/2 遺伝学的検査(コンパニオン診断を除く)を施行した女性乳癌症例の検討（口頭，一般） 2020/11
12.	当院におけるHR（+）HER２（-）進行再発癌に対するEverolimusの治療成績（ポスター掲示，一般） 2020/10
13.	社内研修会(日本イーライリリー) （口頭，特別講演・招待講演など） 2020/09
14.	nab-Paclitaxel起因性末梢神経障害に対する⼿術⼿袋圧迫療法の予防効果の検証：多施設共同第3相試験（口頭，特別講演・招待講演など） 2018/05
5件表示
全件表示(14件)